YTHDF2 and hepatocellular carcinoma: Current developments of small molecule inhibitor (DC‐Y13‐27) targeting YTHDF2 enhanced responses to radiotherapy and immunotherapy,[13] suggesting that targeting YTHDF2 may offer novel combination therapeutic strategies for HCC treatment.